Stock detail
Celcuity (CELC) stock price, chart, and key data
View Celcuity stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Celcuity
CELC · XNAS
$65.80
0.00%
$0.00
Overnight $65.80 (0.00%)
Key metrics
52-week range
$4.25 - $8.00
Close price
$65.80
Market cap
$3.2B
P/E ratio
-45.69
Beta
1.41
About the company
Celcuity Inc
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$155
11
Buy
/ 11
Recent calls
10/26/2026
H.C. Wainwright
Swayampakula Ramakanth
Buy · Price target $155
10/21/2026
TD Cowen
Tara Bancroft
Buy · Price target $145
10/22/2026
Cantor Fitzgerald
Li Watsek
Buy · Price target $140
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app